Bell Investment Advisors, Inc Bei Gene, Ltd. Transaction History

Bell Investment Advisors, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$158.67 - $201.58 $476 - $604	3 Added 100.0%	6 $1,000
Q2 2023 Aug 09, 2023	SELL	$178.3 - $266.78 $356 - $533	-2 Reduced 40.0%	3 $0
Q4 2022 Feb 08, 2023	BUY	$125.51 - $229.3 $376 - $687	3 Added 150.0%	5 $1,000
Q3 2021 Nov 12, 2021	BUY	$249.6 - $403.14 $499 - $806	2 New	2 $1,000

250

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Bell Investment Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Bell Investment Advisors, Inc with notifications on news.